Heparin pharmacovigilance in Brazil.

OBJECTIVE To investigate the biological origin of injectable unfractioned heparin available in Brazilian market by discussing the impact of the profile of commercial products and the changes in heparin monograph on the drug safety. METHODS The Anvisa data base for the Registered Products of Pharmaceutical Companies and the Dictionary of Pharmaceutical Specialties (DEF 2008/2009) were searched. A survey with industries having an active permission for marketing the drug in Brazil was conducted. RESULTS Five companies were granted a permission to market unfractioned heparin in Brazil. Three of them are porcine in origin and two of them are bovine in origin, with only one explicitly showing this information in the package insert. The effectiveness and safety of heparin studied in non-Brazilian populations may not represent the Brazilian reality, since most countries no longer produce bovine heparin. The currently marketed heparin has approximately 10% less anticoagulant activity than that previously produced and this change may have clinical implications. CONCLUSIONS Evidence about the lack of dose interchangeability between bovine and porcine heparins and the unique safety profile of these drugs indicates the need to follow the treatment and the patients' response. Events threatening the patient's safety must be reported to the pharmacovigilance system in each particular country.

• Publication year

  2011

• Venue

  Revista da Associação Médica Brasileira

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2255-4823(11)70067-4PMID 21691698
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Textbook of Pharmacovigilance

  2011cited by this paper
• Changes in the USP Heparin Monograph and Implications for Clinicians

  2010cited by this paper
• Heparins from porcine and bovine intestinal mucosa: Are they similar drugs?

  2010cited by this paper
• Challenges in the quality of heparin

  2009cited by this paper
• The troubled heparin issue in the Brazilian market and the search for solutions.

  2009cited by this paper
• A busca de soluções para o problema das heparinas no mercado nacional

  2009cited by this paper
• Heparinas - Momento atual

  2008cited by this paper
• Outbreak of adverse reactions associated with contaminated heparin.

  2008cited by this paper
• The utility of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children.

  2008cited by this paper
• The financial impact of heparin-induced thrombocytopenia.

  2008cited by this paper
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Heparin quality control in the Brazilian market: implications in the cardiovascular surgery.

  2008cited by this paper
• Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• The FDA and safety—beyond the heparin crisis

  2008cited by this paper
• Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update.

  2006cited by this paper
• Agência Nacional de Vigilância Sanitária

  2004cited by this paper
• Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.

  2003cited by this paper
• Bovine spongiform encephalopathy.

  2003cited by this paper
• Bovine spongiform encephalopathy

  1996cited by this paper
• Frequency of adverse drug reactions [letter; comment]

  1993cited by this paper

• Global Use of Bovine Heparin: Challenges and Opportunities

  2025cites this paper
• Converting the Distinct Heparins Sourced from Bovine or Porcine Mucosa into a Single Anticoagulant Drug

  2019cites this paper
• A Retrospective Study on Unfractionated Bovine Heparin Safety in On-Pump Cardiac Surgery

  2019cites this paper
• Heparins Sourced From Bovine and Porcine Mucosa Gain Exclusive Monographs in the Brazilian Pharmacopeia

  2019cites this paper
• Enzymatic Generation of Highly Anticoagulant Bovine Intestinal Heparin.

  2017cites this paper
• Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

  2017cites this paper
• ASSOCIAÇÃO MÉDICA BRASILEIRA

  2016cites this paper
• Stable isotopic analysis of porcine, bovine, and ovine heparins.

  2015cites this paper
• Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction.

  2013cites this paper
• Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.

  2012cites this paper